IVIG legislation reintroduced
Executive SummaryLegislation regarding the reimbursement rates for intravenous immune globulin therapies has been reintroduced by Sens. John Kerry, D-Mass., and Lamar Alexander, R-Tenn., though this bill is different from a previous effort in that it does not call for the continuation of a pre-administration fee that has been used by physician offices and hospital outpatient centers to cover the cost of IVIG therapies (1"The Pink Sheet," May 12, 2008, p. 32). Instead, the latest version of the legislation, known as "The Medicare Patient IVIG Act," S. 701, directs the HHS secretary to collect data on the costs incurred to obtain IVIG therapies and the amount that is reimbursed, as well as providing the authority over a two-year window to adjust payments as necessary to avoid any access issues. IVIG is reimbursed like other Medicare Part B drugs using an average sales price-based rate for each of the six IVIG products available (ASP+6% in the physician office and ASP+4% in the hospital outpatient setting). Advocacy groups have argued that access to IVIG has suffered from low reimbursement. CMS dropped the pre-administration fee beginning in 2009 (2"The Pink Sheet," Nov. 17, 2008, p. 21)
You may also be interested in...
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.